Please provide your email address to receive an email when new articles are posted on . Selarsdi is approved for the treatment of plaque psoriasis, psoriatic arthritis in adults, patients aged 6 years ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously (directly ...

Credit: Fresenius Kabi. The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara. Patients may now switch ...

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...

A biosimilar version of the multipurpose biologic drug ustekinumab has been approved by the FDA and can be swapped interchangeably with the original product sold as Stelara. The new version carries ...

CSPC PHARMA (01093.HK) announced that the Groups self-developed ustekinumab injection, marketed under the brand name Enyike, ...

The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...

55.2 percent of induction responder patients treated with STELARAat the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without ...